DataSheet_9_Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.xlsx

Programmed death-ligand 1 (PD-L1) expression has been approved as an immune checkpoint inhibitor (ICI) response predictive biomarker; however, the clinicopathological and molecular features of HPV-positive oropharyngeal squamous cell carcinoma [HPV(+)OPSCC] based on PD-L1 expression are not well studied. We aimed to characterize clinicopathological, tumor immune microenvironmental, and molecular features of HPV(+)OPSCC with different PD-L1 expression scored by combined positive score (CPS). A total of 112 cases were collected from 2008-2021 and received PD-L1 and CD8 immunohistochemistry (IHC) staining. 71 samples received DNA sequencing out of which 32 samples received RNA sequencing for immune-related gene alterations or expression analysis. The 32 samples were also subjected to analysis of CD20, CD4, CD8, CD68, Foxp3 and P16 by multiplex immunofluorescence (mIF) staining, and the immune markers were evaluated in the tumor body (TB), tumor margin (TM) and normal stroma (NS) regions separately. Our results showed that of 112 HPV(+)OPSCC tumors, high(CPS≥20), intermediate(1≤CPS

程序性死亡配体1（PD-L1）的表达已被批准为免疫检查点抑制剂（ICI）反应预测性生物标志物；然而，基于PD-L1表达的人乳头瘤病毒阳性（HPV(+)）口咽鳞状细胞癌（HPV(+)OPSCC）的病理学和分子特征研究尚不充分。本研究旨在描述不同PD-L1表达评分（联合阳性评分，CPS）下的人乳头瘤病毒阳性（HPV(+)）口咽鳞状细胞癌（HPV(+)OPSCC）的病理学、肿瘤免疫微环境和分子特征。共收集了2008-2021年间的112个病例，并进行了PD-L1和CD8免疫组化（IHC）染色。其中71个样本接受了DNA测序，其中32个样本接受了RNA测序以分析免疫相关基因的变异或表达。这32个样本还通过多重免疫荧光（mIF）染色分析了CD20、CD4、CD8、CD68、Foxp3和P16，并在肿瘤实体（TB）、肿瘤边缘（TM）和正常基质（NS）区域分别评估了免疫标志物。我们的研究结果表明，在112个人乳头瘤病毒阳性（HPV(+)）口咽鳞状细胞癌（HPV(+)OPSCC）肿瘤中，高（CPS≥20）、中（1≤CPS<20）和低（CPS<1）PD-L1表达组的特征各异。